Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$779000.0.

  • Lyell Immunopharma's Change in Account Payables fell 3714.79% to -$779000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 50802.07%. This contributed to the annual value of -$3.2 million for FY2024, which is 32090.16% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Change in Account Payables is -$779000.0, which was down 3714.79% from -$231000.0 recorded in Q2 2025.
  • Lyell Immunopharma's Change in Account Payables' 5-year high stood at $2.9 million during Q1 2022, with a 5-year trough of -$2.0 million in Q4 2024.
  • In the last 5 years, Lyell Immunopharma's Change in Account Payables had a median value of -$231000.0 in 2025 and averaged -$193473.7.
  • In the last 5 years, Lyell Immunopharma's Change in Account Payables soared by 36324.92% in 2022 and then crashed by 623043.48% in 2023.
  • Lyell Immunopharma's Change in Account Payables (Quarter) stood at $99000.0 in 2021, then tumbled by 631.31% to -$526000.0 in 2022, then soared by 180.8% to $425000.0 in 2023, then plummeted by 579.06% to -$2.0 million in 2024, then surged by 61.74% to -$779000.0 in 2025.
  • Its last three reported values are -$779000.0 in Q3 2025, -$231000.0 for Q2 2025, and -$1.7 million during Q1 2025.